Asset Management Equity Business Thematic

Asset Management Equity Business Thematic

March 2016
Asset Management Equity Business
Thematic Equities: Security & Safety
The coming disruption in the healthcare industry: Opportunities for security & safety investors?
Dr. Patrick Kolb, Fund Manager, Credit Suisse
«One of the greatest pains to human nature is the pain of a new idea»
Walter Bagehot
Dear Reader
Healthcare costs are a growing burden for our society and we strongly believe it will continue to rise in the long
run. Just looking at the United States, the general budget trends are worrisome: The Congressional Budget Office
of the United States (CBO) recently published the budget and economic outlook from 2015 to 2025. According to
their projections, the US budget deficit in 2025 is projected to be USD 1.1 trillion (or 4.0% of GDP) and the
cumulative deficits over the 2016 – 2025 period are projected to total USD 7.6 trillion1. The key factors for that
persistent deficit are the retirement of the baby-boom generation, the expansion of federal subsidies for health
insurance, increasing healthcare costs per beneficiary and rising interest rates on federal debt. As of 2025 nearly a
quarter of US GDP will be spent on healthcare alone, compared to around 16.4% as of today2.
Clearly, long-term budget projections are highly uncertain. Trends such as the aging of the population or the
growth in per capita spending on healthcare are expected to significantly increase public spending even beyond
2025. If the current system remains, the CBO estimates that federal public debt would exceed 100 percent of
GDP by 2039. This is about equal to the percentage recorded just after the Second World War3.
We believe such a cost development is not sustainable. Just take an example from the healthcare industry: On
average it currently takes up to 12 years and USD 2.5 billion4 to develop a new drug, and only five in 5’000 of
these new drugs are making it to human testing and only one of the five will be approved by the Food and Drug
Source: CBO (2015): The Budget and Economic Outlook: 2015 to 2025, p. 15, URL: https://www.cbo.gov/publication/49892,
7.3.2016.
2
Source: OECD Health Statistics (2015): Focus on Health Spending, July 2015, p. 2, URL: http://www.oecd.org/els/ healthsystems/health-data.htm, 7.3.2016.
3
Source: CBO (2015): The Budget and Economic Outlook: 2015 to 2025, p. 26, URL: https://www.cbo.gov/publication/49892,
7.3.2016.
4
Source: Scientific American (2014): Cost to Develop New Pharmaceutical Drug Now Exceeds $2.5B, in: Scientific American, Nov. 24th
2014, URL: http://www.scientificamerican.com/article/cost-to-develop-new-pharmaceutical-drug-now-exceeds-2-5b/, 16.3.2016.
1
Page 1 of 5
March 2016
Administration (FDA) for human use5. In our opinion, novel approaches in technology are urgently needed to
mitigate this cost trend in the healthcare industry.
Can technology mitigate rising healthcare costs?
The Singularity University in San Diego, USA is organizing every year the exponential medicine conference. Their
aim is to explore how technology can reshape the healthcare sector. According to the proponents this industry has
to shift from a symptom/fee-based and reactive model to a predictive and value-based medicine. Scientists are
predicting fascinating future trends in this field and believe technology is going to revolutionize the entire healthcare
industry6. In this context we want to highlight three interesting areas:
1) Genomics: The cost of Fig. 1: The costs of DNA sequencing
DNA sequencing has
been declining 3-times
faster than Moore’s Law7
would foresee, plummeting from USD 100
million per genome in
2001 to about USD
1’000 per genome today
(fig. 1)8. It is expected
that by 2019 more than
two billion genomes will
be sequenced, including
50
million
human
9
genomes .
When
a
person’s
sequenced
genome is compared to
millions of other people’s
genome and other health Source: Nature (2014)
datasets,
big
data
technologies such as machine learning and data mining technique can analyse certain traits of health risks
or diseases and recommend possible prevention measures, treatment or therapies10.
2) Artificial intelligence: As an example, Johnson & Johnson, the world’s premier manufacturer of
healthcare products, is collaborating with IBM Watson Health, a question answering computer system
developed by IBM. This IT system uses more than 100 different techniques to identify and analyse sources
and evidences11. Their aim is to conceptualise about how to read and understand scientific papers and
Source: Lipsky et al. (2001): From Idea to Market: The Drug Approval Process, in: Journal of the American Board of Family Medicine,
Sept./Oct. 2001, p. 365, URL: http://www.jabfm.org/content/14/5/362.full.pdf+html, 7.3.2016.
6
Source: Diamandis (2015): Exponential Medicine: Healthcare Is Broken, Here’s How We’re Going Fix It, URL:
http://singularityhub.com/2015/11/10/exponential-medicine-healthcare-is-broken-heres-how-we-are-going-fix-it/, 8.3.2016.
7
According to the Moore’s law, processing power doubles roughly every two years as smaller transistors are packed ever more tightly onto
silicon wafers, boosting performance and reducing costs (source: Moore, G. (1965): Cramming More Components onto Integrated Circuits,
in: Electronics, pp. 114 – 117, April 19th 1965)).
8
Source: Nature (2014): Technology: The USD 1’000 genome, in: Nature, March 19 th 2014, URL:
http://www.nature.com/news/technology-the-1-000-genome-1.14901, 11.3.2016.
9
Source: ARK Invest (2014): Heading for USD 100: The Declining Costs of Genome Sequencing & The Consequences, Aug. 21st 2014,
URL: http://ark-invest.com/genomic-revolution/declining-costs-of-genome-sequencing, 14.3.2016.
10
Source: MIT Review (2016): DNA App Store, in: MIT Technology Review: 10 Breakthrough Technologies, Vol. 119, Nr. 2, March/April
2016, p. 53.
11
IBM Watson is a cognitive system designed to mirror the human learning process, but without the burden of biases arising from memory
and the limitation of time. In a world of rapidly expanding data the latter is particularly important. Humans alone simply cannot make sense of
all of the information being produced every day (Source: IBM (2011): DeepQA Project: FAQ, URL:
http://researcher.watson.ibm.com/researcher/view_group_subpage.php?id=2159, 14.3.2016)).
5
Page 2 of 5
March 2016
clinical trial outcomes12. According to the Memorial Sloan-Kettering Cancer Center in New York, a human
doctor needs at least 160 hours of reading every week just to keep up with the latest medical knowledge.
IBM Watson Health has processed more than 2 million medical journal pages and 1.5 million patient
records. In tests, IBM Watson Health’s successful diagnosis for lung cancer is 90 percent (compared with
50 percent for human doctors)13.
3) Robotics: Increased precision, accuracy and mobility of medical robots will improve surgical outcomes and
enable more patients to receive treatments. Going forward we expect the development of a new
generation of surgical robots which can conduct autonomously routine surgeries without human error at a
lower cost.
The cost savings within the global healthcare sector could exceed USD 1 trillion by 2025, according to a study by
the George Mason University. This is mainly driven by productivity gains through usage of big data, machine-tomachine communication technologies, smart device monitoring and adaptation14. McKinsey calculates that the use
of big data technologies could reduce healthcare costs in the US alone by up to USD 450 billion. Especially
individual screening of patients combined with an assessment of personal health risks can result in patient-specific
treatment15. Additionally, a recently published five year case study conducted by St. Jude Medical, a provider of
cardiovascular products, showed that remote heart patient monitoring results in cost savings of over USD 370’000
per 100 patients annually. The study itself covered 90’000 participants with pacemakers, implantable cardioverter
defibrillators (ICDs) or cardiac resynchronization therapy (CRT) and found that over USD 333 million for
unnecessary hospitalisations and hospital days were avoided16.
Conclusion
Although the healthcare industry has lagged in the use of big data to other sectors such as the retail industry —
partly because of concerns about patient confidentiality — we believe it could soon catch up. In our opinion this
sector is going to undergo disruptive changes, due to the exponential growth of data such as medical records,
clinical research, digitized diagnostics, sensors or wearable devices. First movers in this area are already achieving
positive results, which is surely prompting competitors to take action. These developments are encouraging for
consumers, patients and taxpayers, but they also raise an important question: Is the healthcare industry prepared
to capture the full potential?
At Credit Suisse, we believe that disruptive technologies in the field of human healthcare is in its first inning of its
growth rate. But, as it has been recently reported in the Financial Times, we also think about possible
consequences from a security and safety point of view17. As our society becomes digitized and people rely more
and more on computers, cyber risks (including data breaches and data losses) will grow. Therefore we believe an
adequate privacy policy and excellent data protection are necessary conditions to be fulfilled, otherwise the
discussed cost saving potential will be rather limited. As a consequence we are long term shareholders of leading
companies with a special focus on safety and security such as big data analytics, data protection and encryption.
For further information (such as current fund factsheet, performance or quarterly comments) please click here.
Source: Johnson & Johnson (2015): Johnson & Johnson and IBM Announce Plans to Collaborate on Advanced Solutions Designed to
Transform Healthcare Delivery, media release, April 13th 2015, URL: http://www.jnj.com/news/all/Johnson-Johnson-and-IBM-AnnouncePlans-to-Collaborate-on-Advanced-Solutions-Designed-to-Transform-Healthcare-Delivery, 14.3.2016.
13
Source: Steadman (2013): IBM's Watson is better at diagnosing cancer than human doctors, in: Wired, Feb. 11 th 2013, URL:
http://www.wired.co.uk/news/archive/2013-02/11/ibm-watson-medical-doctor, 14.3.2016.
14
Source: Thierer/Castillo (2015): Projecting the growth and economic impact of the internet of things, June 2015, in: Economic
Perspectives, p. 2, URL: http://mercatus.org/publication/projecting-growth-and-economic-impact-internet-things, 8.3.16.
15
Source: McKinsey (2013): The big-data revolution in US health care: Accelerating value and innovation, April 2013, URL:
http://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/the-big-data-revolution-in-us-health-care, 11.3.2016.
16
Source: Settles (2015): Remote Patient Monitoring in Healthcare, in: TechnologyAdvice, June 15th 2015, URL:
http://technologyadvice.com/medical/blog/remote-patient-monitoring/, 14.3.2016.
17
See Financial Times (2016): Healthcare sector warned to be alert for hack attacks, in: The Financial Times, The Connected Business,
Special Report, March 2nd 2016, p. 3.
12
Page 3 of 5
March 2016
CREDIT SUISSE AG
credit-suisse.com
DISCLAIMER
The information provided herein constitutes marketing material. It is not investment advice or otherwise based on a consideration of the personal circumstances of the addressee nor
is it the result of objective or independent research. The information provided herein is not legally binding and it does not constitute an offer or invitation to enter into any type of
financial transaction.
The information provided herein was produced by Credit Suisse AG and/or its affiliates (hereafter "CS") with the greatest of care and to the best of its knowledge and belief.
The information and views expressed herein are those of CS at the time of writing and are subject to change at any time without notice. They are derived from sources believed to
be reliable.
CS provides no guarantee with regard to the content and completeness of the information and does not accept any liability for losses that might arise from making use of the
information. If nothing is indicated to the contrary, all figures are unaudited. The information provided herein is for the exclusive use of the recipient.
Equities are subject to market forces and hence fluctuations in value, which are not entirely predictable.
Neither this information nor any copy thereof may be sent, taken into or distributed in the United States or to any U. S. person (within the meaning of Regulation S under the US
Securities Act of 1933, as amended).
It may not be reproduced, neither in part nor in full, without the written permission of CS.
Copyright © 2016 Credit Suisse Group AG and/or its affiliates. All rights reserved.
Luxembourg
This document is distributed by CREDIT SUISSE (LUXEMBOURG) S.A. (“CSLux”), which is authorized as a credit institution in the Grand Duchy of Luxembourg and under the
prudential supervision of the Luxembourg supervisory authority of the financial sector, the Commission de Surveillance du Secteur Financier (CSSF), 110, route d'Arlon, L-2991
and part of the Credit Suisse group. This document has been prepared by CS AG and not by CSLux.
CSLux was not involved in the production of this document. CSLux provides no guarantee with regard to its content and completeness and does not accept any liability for losses
which might arise from making use of this information.
This document constitutes marketing material. It does not constitute investment research. It has not been prepared in accordance with legal requirements designed to promote the
independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This document is intended only to provide general and preliminary information and shall not be construed as the basis for any investment decision nor as an offer or a solicitation to
conclude a transaction in financial instruments or to subscribe to banking services. The liability of CSLux may not be engaged as regards any investment, divestment or retention
decision taken by an investor/recipient on the basis of this document. Each investor/recipient shall make his/her own appraisal of the tax, legal, accounting and other financial
merits and risks of his/her investment regardless of the opinion expressed in the document. An investor must particularly ensure the suitability of his/her investment as regards
his/her financial and fiscal situation, his knowledge and experience in financial instruments and his/her investment objectives. The investor bears all the risks of losses in connection
with his/her investment.
This document shall not be construed as a personal recommendation as regards the financial instruments/investment strategies mentioned in the material. This document does not
constitute an investment advice, it does not take into account the recipient’s economic situation, his/her current assets or liabilities, his/her knowledge and experience in financial
instruments and markets, his/her investment purposes, investment horizon, risk profile and preferences.
This document is addressed to the recipient on the basis of the recipient’s explicit request. This document is for the exclusive use of the recipient. Any use of this information by the
recipient is under the sole responsibility of the recipient. This document may not be reproduced or disseminated either in part or in full without the written permission of CSLux. This
document is not intended for persons who, due to their nationality or place of residence, are not permitted to receive such information under local law. Neither this document nor any
copy thereof may be sent, taken into or distributed in the United States or to any U. S. person (within the meaning of Regulation S under the US Securities Act of 1933, as
amended).
Copyright © 2016 CREDIT SUISSE (LUXEMBOURG) S.A., registered office: 5, rue Jean Monnet, L-2180 Luxembourg, Grand Duchy of Luxembourg, R.C.S. Luxembourg n° B
11756. All rights reserved.
Liechtenstein
For institutional investors only. The shares offered are exclusively offered to a limited group of investors, in all cases and under all circumstances designed to preclude a public
solicitation in Liechtenstein. This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have
personally been sent. This offer is a private offer, this material and the transactions described therein are therefore not nor have been subject to the review and supervision of the
Liechtenstein Financial Market Authority.
Nur für institutionelle Anleger. Das Zeichnungsangebot ist einer begrenzten Anlegergruppe vorbehalten. Ein öffentliches Angebot in Liechtenstein ist in allen Fällen und unter allen
Umständen ausgeschlossen. Das vorliegende Dokument darf nicht zu anderen Zwecken verwendet oder vervielfältigt werden und ist ausschliesslich für Personen bestimmt, denen
das Dokument persönlich zugesendet wurde. Bei diesem Angebot handelt es sich um ein privates Zeichnungsangebot. Die vorliegenden Unterlagen und die darin beschriebenen
Transaktionen unterliegen deshalb nicht der Aufsicht und Überprüfung durch die Finanzmarktaufsicht Liechtenstein.
Italy
Performance indications do not consider commissions levied at subscription and/or redemption. Furthermore, no guarantee can be given that the performance of the benchmark will
be reached or outperformed.
Financial instruments mentioned in this document could be considered complex products and therefore may not be suitable for retail clients.
PERFORMANCE OBTAINED IN THE PAST DOES NOT CONSTITUTE ANY WARRANTY FOR FUTURE.
BEFORE THE SUBSCRIPTIONS READ THE PROSPECTUS.
CREDIT SUISSE (ITALY) S.P.A. - Via Santa Margherita, 3 - 20121 Milano – italy.csam@credit-suisse.com - www.credit-suisse.com/it
Spain
Page 4 of 5
March 2016
For institutional clients only
When distributed in Spain is is distributed by CREDIT SUISSE (ITALY) S.P.A. - Via Santa Margherita, 3 - 20121 Milano – italy.csam@credit-suisse.com - www.credit-suisse.com/it
UK
For Qualified Investors/Institutional Clients Only.
When distributed from the United Kingdom, this is distributed by Credit Suisse Asset Management Limited which is authorized and regulated by the Financial Conduct Authority.
France
This document can only be offered to professional clients and to eligible counterparties. This document is distributed by Credit Suisse (Luxembourg) S.A., Succursale en France
When distributed in France, this is distributed by Credit Suisse (Luxembourg) S.A., Succursale en France which is authorized and regulated by Autorité de Contrôle Prudentiel et de
Résolution (ACPR) and l’Autorité des Marchés Financiers (AMF).
Dubai
This presentation can only be offered to Professional Clients. This material is personal to each offeree and may only be used by those persons to whom it has been handed out.
Sweden/Denmark/Norway/Netherlands
For Qualified Investors/Institutional Clients Only
Germany and Austria
Wichtige Hinweise
Dieses Dokument wurde von der Division Private Banking & Wealth Management von Credit Suisse («Credit Suisse») und nicht von der Research-Abteilung von Credit Suisse
erstellt. Es stellt keine Finanzanalyse dar und genügt deshalb nicht allen gesetzlichen Anforderungen zur Gewährleistung der Unvoreingenommenheit von Finanzanalysen und
unterliegt keinem Verbot des Handels vor der Veröffentlichung von Finanzanalysen.
Bei diesem Dokument handelt es sich um eine Werbemitteilung, die ausschließlich zu Werbezwecken verbreitet wird. Dieses Dokument dient ausschliesslich zur Information und
Veranschaulichung sowie zur Nutzung durch den Empfänger. Es stellt weder eine Aufforderung noch ein Angebot zur Zeichnung oder zum Erwerb der darin erwähnten Produkte und
Dienstleistungen dar. Bei den darin enthaltenen Informationen handelt es sich lediglich um allgemeine Marktkommentare und in keiner Weise um regulierte Finanzberatung bzw.
Rechts-, Steuer- oder andere regulierte Finanzdienstleistungen. Den finanziellen Zielen, Verhältnissen und Bedürfnissen einzelner Personen wird keine Rechnung getragen. Diese
müssen indes berücksichtigt werden, bevor eine Anlageentscheidung getroffen wird. Die hierin enthaltenen Informationen sind nicht ausreichend, um eine Anlageentscheidung zu
treffen, und stellen keine persönliche Empfehlung oder Anlageberatung dar. Sie bringen lediglich die Einschätzungen und Meinungen der betreffenden einzelnen Mitarbeiter von
Private Banking & Wealth Management zum Zeitpunkt der Erstellung des Dokuments zum Ausdruck und beziehen sich nicht auf das Datum, an dem der Leser die Informationen
erhält oder darauf zugreift.
Die Einschätzungen und Meinungen der Mitarbeiter von Private Banking & Wealth Management können von den Einschätzungen und Meinungen der Analysten von Credit Suisse
oder von anderen Mitarbeitern von Credit Suisse Private Banking & Wealth Management oder den Eigenpositionen von Credit Suisse abweichen oder können diesen widersprechen.
Sie können sich zudem jederzeit ohne Benachrichtigung ändern und es besteht keine Verpflichtung, die Angaben zu aktualisieren. Sofern dieses Dokument Aussagen über künftige
Wertentwicklungen enthält, sind diese Aussagen zukunftsgerichtet und bergen daher diverse Risiken und Ungewissheiten.
Die in diesem Dokument enthaltenen Informationen und Meinungen stammen aus oder basieren auf Quellen, die von Credit Suisse als zuverlässig erachtet werden; dennoch
garantiert Credit Suisse weder deren Richtigkeit noch deren Vollständigkeit. Credit Suisse lehnt jede Haftung für Verluste ab, die aufgrund der Verwendung dieses Dokuments
entstehen. Ist nichts anderes vermerkt, sind alle Zahlen ungeprüft. Sämtliche hierin erwähnten Bewertungen unterliegen den Bewertungsrichtlinien und -prozessen von Credit
Suisse. Zu beachten ist, dass historische Wertentwicklungen und Finanzmarktszenarien kein verlässlicher Indikator für laufende und zukünftige Ergebnisse sind.
Mit jeder Anlage sind Risiken verbunden und unter volatilen oder unsicheren Marktbedingungen können der Wert und die Rendite der Anlage stark fluktuieren. Bei Anlagen in
ausländischen Wertschriften oder Fremdwährungen besteht zusätzlich das Risiko, dass die ausländische Wertschrift oder die Fremdwährung gegenüber der Referenzwährung des
Anlegers an Wert verliert. Alternative Anlageprodukte und -strategien (wie Hedge Fonds und Private Equity) können komplex sein und höhere Risiken beinhalten. Diese Risiken
können sich aus dem ausgedehnten Einsatz von Leerverkäufen, Derivaten und Leverage ergeben. Zudem kann der Mindestanlagezeitraum für solche Anlagen länger sein als bei
traditionellen Anlageprodukten. Alternative Anlagestrategien (wie Hedge Fonds) sind nur für Anleger bestimmt, welche die mit diesen Anlagen verbundenen Risiken verstehen und
akzeptieren.
Dieses Dokument ist nicht für die Verbreitung an oder die Nutzung durch natürliche oder juristische Personen bestimmt, die Bürger eines Landes sind oder die in einem Land ihren
Wohnsitz bzw. ihren Gesellschaftssitz haben, in dem die Verbreitung, Veröffentlichung, Bereitstellung oder Nutzung geltende Gesetze oder Vorschriften verletzen würde oder in dem
Credit Suisse und/oder ihre Tochtergesellschaften oder verbundenen Unternehmen Registrierungs- oder Zulassungspflichten erfüllen müssten. Die Unterlagen wurden dem
Empfänger zur Verfügung gestellt und dürfen nicht ohne die ausdrückliche schriftliche Genehmigung von Credit Suisse weitergegeben werden.
In Deutschland wird das vorliegende Dokument von der Credit Suisse (Deutschland) AG verteilt bzw. bereitgestellt, die von der Bundesanstalt für Finanzdienstleistungsaufsicht
(BaFin) zugelassen ist und von ihr beaufsichtigt wird.
Copyright © 2016. CREDIT SUISSE GROUP AG und/oder verbundene Unternehmen. Alle Rechte vorbehalten.
CREDIT SUISSE (DEUTSCHLAND) AKTIENGESELLSCHAFT
Junghofstraße 16
D-60311 Frankfurt am Main
Page 5 of 5